WallStreetZenWallStreetZen

NASDAQ: CBAY
Cymabay Therapeutics Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for CBAY

Based on 2 analysts offering 12 month price targets for Cymabay Therapeutics Inc.
Min Forecast
$8.00+102.53%
Avg Forecast
$9.00+127.85%
Max Forecast
$10.00+153.16%

Should I buy or sell CBAY stock?

Based on 2 analysts offering ratings for Cymabay Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CBAY stock forecasts and price targets.

CBAY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
B. Riley Securities
Top 2%
99
Strong BuyMaintains$8.00+102.53%2022-05-18
HC Wainwright & Co.
Bottom 4%
4
BuyMaintains$10.00+153.16%2022-05-16

1 of 1

Forecast return on equity

Is CBAY forecast to generate an efficient return?
Company
11.26%
Industry
14.69%
Market
64.75%
CBAY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CBAY forecast to generate an efficient return on assets?
Company
4.25%
Industry
13.16%
CBAY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CBAY earnings per share forecast

What is CBAY's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
-$1.21
Avg 2 year Forecast
-$1.26
Avg 3 year Forecast
-$0.76

CBAY revenue forecast

What is CBAY's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$50.5M
Avg 2 year Forecast
$55.0M
Avg 3 year Forecast
$77.3M

CBAY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CBAY$3.95$9.00+127.85%Strong Buy
OCGN$1.52$5.88+286.51%Strong Buy
NSTG$7.12$32.40+355.06%Buy
ADAP$2.02$4.13+104.21%Buy
PEPG$14.00$22.50+60.71%Strong Buy

Cymabay Therapeutics Stock Forecast FAQ

Is Cymabay Therapeutics Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CBAY) stock is to Strong Buy CBAY stock.

Out of 2 analysts, 1 (50%) are recommending CBAY as a Strong Buy, 1 (50%) are recommending CBAY as a Buy, 0 (0%) are recommending CBAY as a Hold, 0 (0%) are recommending CBAY as a Sell, and 0 (0%) are recommending CBAY as a Strong Sell.

If you're new to stock investing, here's how to buy Cymabay Therapeutics stock.

What is CBAY's earnings growth forecast for 2022-2024?

(NASDAQ: CBAY) Cymabay Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.96%.

Cymabay Therapeutics's earnings in 2022 is -$105,911,000.On average, 8 Wall Street analysts forecast CBAY's earnings for 2022 to be -$102,464,086, with the lowest CBAY earnings forecast at -$115,166,246, and the highest CBAY earnings forecast at -$79,600,199. On average, 7 Wall Street analysts forecast CBAY's earnings for 2023 to be -$106,698,139, with the lowest CBAY earnings forecast at -$119,400,299, and the highest CBAY earnings forecast at -$66,051,229.

In 2024, CBAY is forecast to generate -$64,357,608 in earnings, with the lowest earnings forecast at -$105,004,518 and the highest earnings forecast at $13,548,970.

What is CBAY's revenue growth forecast for 2022-2024?

(NASDAQ: CBAY) Cymabay Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.76%.

Cymabay Therapeutics's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast CBAY's revenue for 2022 to be $4,276,393,682, with the lowest CBAY revenue forecast at $4,276,393,682, and the highest CBAY revenue forecast at $4,276,393,682. On average, 1 Wall Street analysts forecast CBAY's revenue for 2023 to be $4,657,458,465, with the lowest CBAY revenue forecast at $4,657,458,465, and the highest CBAY revenue forecast at $4,657,458,465.

In 2024, CBAY is forecast to generate $6,542,967,014 in revenue, with the lowest revenue forecast at $2,684,389,697 and the highest revenue forecast at $14,607,483,368.

What is CBAY's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: CBAY) forecast ROA is 4.25%, which is lower than the forecast US Biotechnology industry average of 13.16%.

What is CBAY's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CBAY price target, the average CBAY price target is $9.00, with the highest CBAY stock price forecast at $10.00 and the lowest CBAY stock price forecast at $8.00.

On average, Wall Street analysts predict that Cymabay Therapeutics's share price could reach $9.00 by May 18, 2023. The average Cymabay Therapeutics stock price prediction forecasts a potential upside of 127.85% from the current CBAY share price of $3.95.

What is CBAY's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: CBAY) Cymabay Therapeutics's current Earnings Per Share (EPS) is -$1.26. On average, analysts forecast that CBAY's EPS will be -$1.21 for 2022, with the lowest EPS forecast at -$1.36, and the highest EPS forecast at -$0.94. On average, analysts forecast that CBAY's EPS will be -$1.26 for 2023, with the lowest EPS forecast at -$1.41, and the highest EPS forecast at -$0.78. In 2024, CBAY's EPS is forecast to hit -$0.76 (min: -$1.24, max: $0.16).

What is CBAY's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: CBAY) forecast ROE is 11.26%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.